Back to Search Start Over

A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices

Authors :
Federico Ravaioli
M. Rosselli
Giuseppe Mazzella
Mirella Fraquelli
Antonio Colecchia
Corina Rusu
Nathalie Ganne-Carrié
Giovanni Marasco
Paul Calès
Davide Festi
Horia Stefanescu
Victor de Ledinghen
Pietro Andreone
Stefanescu H.
Marasco G.
Cales P.
Fraquelli M.
Rosselli M.
Ganne-Carrie N.
de Ledinghen V.
Ravaioli F.
Colecchia A.
Rusu C.
Andreone P.
Mazzella G.
Festi D.
Regional Institute of Gastroenterology and Hepatology [Cluj-Napoca]
Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH)
Université d'Angers (UA)
II Gastroenterology Unit, Department of Medicine
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Physiopathologie du cancer du foie
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2
Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO)
Source :
Liver International, Liver International, Wiley-Blackwell, 2019, 40 (1), pp.175-185. ⟨10.1111/liv.14228⟩
Publication Year :
2019

Abstract

Background & Aims Several non-invasive tests (NITs) have been developed to diagnose oesophageal varices (EV), including the recent Baveno VI criteria to rule out high-risk varices (HRV). Spleen stiffness measurement (SSM) with the standard FibroScan (R) (SSM@50Hz) has been evaluated. However, the EV grading could be underestimated because of a ceiling threshold (75 kPa) of the SSM@50Hz. The aims were to evaluate SSM by a novel spleen-dedicated FibroScan (R) (SSM@100Hz) for EV diagnosis compared with SSM@50Hz, other validated NITs and Baveno VI criteria. Methods This prospective multicentre study consecutively enrolled patients with chronic liver disease; blood data, endoscopy, liver stiffness measurement (LSM), SSM@50Hz and SSM@100Hz were collected. Results Two hundred and sixty patients met inclusion criteria. SSM@100Hz success rate was significantly higher than that of SSM@50Hz (92.5% vs 76.0%, P < .001). SSM@100Hz accuracy for the presence of EV (AUC = 0.728) and HRV (AUC = 0.756) was higher than in other NITs. SSM@100Hz AUC for large EV (0.782) was higher than SSM@50Hz (0.720, P = .027). AUC for HRV with SSM@100Hz (0.780) was higher than with LSM (0.615, P < .001). The spared endoscopy rate of Baveno VI criteria (8.1%) was significantly increased by the combination to SSM@50Hz (26.5%) or SSM@100Hz (38.9%, P < .001 vs others). The missed HRV rate was, respectively, 0% and 4.7% for combinations. Conclusions SSM@100Hz is a new performant non-invasive marker for EV and HRV providing a higher accuracy than SSM@50Hz and other NITs. The combination of Baveno VI criteria and SSM@100Hz significantly increased the spared endoscopy rate compared to Baveno VI criteria alone or combined with SSM@50Hz. Clinical trial number: NCT02180113.

Details

ISSN :
14783231 and 14783223
Volume :
40
Issue :
1
Database :
OpenAIRE
Journal :
Liver international : official journal of the International Association for the Study of the LiverREFERENCES
Accession number :
edsair.doi.dedup.....4e53e6699bd2cb7279cc77d314e389f5